Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumour immunity to further improve outcomes for patients affected by cancer.
When harnessed appropriately, the immune system is an extremely potent and specific endogenous anti-tumour mechanism. Our first-in-class agonist antibody has been designed to address current clinical challenges associated with immunotherapy such as improving the rate and quality of responses, while also addressing the clinical challenges that have been encountered with recombinant IL-21.
Company Details
- Founded
- 2021
- Address
- 407 Royal Pde, Parkville,victoria 3052,australia
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.piotx.com/
- Keywords
- humble bee bio.
- HQ
- Parkville, Victoria
Pio Therapeutics Pty Ltd Questions
Pio Therapeutics Pty Ltd's website is https://www.piotx.com/
Pio Therapeutics Pty Ltd's LinkedIn profile is https://au.linkedin.com/company/piotherapeutics
Pio Therapeutics Pty Ltd's industry is
Pharmaceutical Manufacturing
Pio Therapeutics Pty Ltd's top competitors are
Cellphire Therapeutics, Inc.,
360biolabs, A Bioagilytix Company,
Brandon Capital,
Biopacific Partners,
Novo Nordisk Foundation Center For Stem Cell Medicine – Renew,
Central Pharmacy Logistics Australia,
Humble Bee Bio,
Biocurate Pty Ltd,
Sonnet Biotherapeutics,
Phrenix Therapeutics.
Pio Therapeutics Pty Ltd's categories are Pharmaceutical Manufacturing
Pio Therapeutics Pty Ltd's founding year is 2021
